Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.50 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.50 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 10/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16033617 | 0.86 | KDM4C (0.67) | KDM4CKDM5AKDM2BKDM5BGRM5 | |
| SCHEMBL16033732 | 0.73 | KDM4C (0.61) | KDM4CKDM5AKDM5BMAPK14 | |
| SCHEMBL16033165 | 0.72 | KDM4C (0.67) | KDM4CKDM5AKDM2BKDM5BMAPK14 | |
| SCHEMBL16033866 | 0.71 | KDM4C (0.69) | KDM4CKDM2BMAPK14 | |
| SCHEMBL16034273 | 0.70 | KDM4C (0.69) | KDM4CKDM2BMAPK14 | |
| SCHEMBL16033590 | 0.69 | KDM4C (0.67) | KDM4CKDM5AKDM2BKDM5BMAPK14 | |
| SCHEMBL16032963 | 0.69 | KDM4C (0.64) | KDM4CKDM5AKDM2BKDM5BSCN2A | |
| SCHEMBL16034027 | 0.69 | KDM4C (0.62) | KDM4CKDM5AKDM2BKDM5BMAPK14 | |
| SCHEMBL44890 | 0.68 | NOTUM (0.58) | GRM5 | |
| SCHEMBL16075698 | 0.68 | KDM4C (0.64) | KDM4CKDM5AKDM2BKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273222-B2 | Histone demethylase inhibitors | CELGENE QUANTSCEL RESEARCH, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273222-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM5A 8/4885KDM2B 19/4885 |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM5A 8/4885KDM2B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.